Reviewing Altimmune (NASDAQ:ALT) and Altamira Therapeutics (NASDAQ:CYTO)

Altamira Therapeutics (NASDAQ:CYTO) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

Altamira Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Altamira Therapeutics and Altimmune, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altamira Therapeutics	0	0	0	0	0.00
Altimmune	0	2	5	1	2.88

Altimmune has a consensus target price of $20.00, suggesting a potential upside of 127.53%. Given Altimmune’s stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Altamira Therapeutics.

Insider and Institutional Ownership

1.9% of Altamira Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 13.0% of Altamira Therapeutics shares are held by company insiders. Comparatively, 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Altamira Therapeutics and Altimmune”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altamira Therapeutics	$320,000.00	5.09	-$4.31 million	N/A	N/A
Altimmune	$430,000.00	1,453.83	-$88.45 million	($1.55)	-5.67

Altamira Therapeutics has higher earnings, but lower revenue than Altimmune.

Profitability

This table compares Altamira Therapeutics and Altimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altamira Therapeutics	N/A	N/A	N/A
Altimmune	-199,076.92%	-55.81%	-50.60%

Summary

Altimmune beats Altamira Therapeutics on 7 of the 13 factors compared between the two stocks.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.